2021
NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted. NeoVanc was a European, multicentre research study coordinated by Penta and funded by the European Commissionâs 7th Framework Programme. It compared the efficacy, safety and pharmacokinetics of an optimised dosing regimen with a standard dosing regimen of vancomycin in infants with late onset sepsis.
2021
Padova – Italy, November 27th 2021
NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted:
2021
WHO has launched a public call for comments on the draft of WHO Essential Medicines List Antibiotic Book.
The book provides guidance on the prescribing and use of the antibiotics on the WHO Model List of Essential Medicines for over 30 common infections in both the community and hospital setting for children and adults. The draft publication has been developed by an international expert working group of specialists in infectious diseases,
2020
The second trial in neonatal sepsis sponsored by Penta is now in its final stretch towards completion. This trial is part of the NeoVanc project, which aimed to analyze the adaptability of an off-label medicine, vancomycin, to the specific needs of neonates and infants, by developing an optimal dosing regimen. Coordinated by Penta and funded by the European Commissionâs 7th Framework Programme, NeoVanc has successfully recruited almost 250 participants, and involved more than 20 sites in 5 European countries.
2020
There is an urgent global need for more child-friendly antibiotic formulations. Our collaborator Prof. Mike Sharland, together with GARDP and St. Georgeâs, University of London researchers have just published a new paper in the WHO Bulletin investigating international antibiotic sales data of child-appropriate oral formulations of antibiotics, with a focus on dispersible tablets. Globally most child-appropriate oral antibiotics were not sold as dispersible tablets,
2020
Authors: Hill LF, Turner MA, Lutsar I, et al; NeoVanc Consortium.
Published in: Trials. 2020;21(1):329
2020
Authors: DonĂ D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M
Published in: Antimicrob Resist Infect Control.2020;9:3
Background Antibiotics are the most common medicines prescribed to children in hospitals and the community, with a high proportion of potentially inappropriate use. Antibiotic misuse increases the risk of toxicity, raises healthcare costs, and selection of resistance.
2019
Authors: Folgori L, Lutsar I, Standing JF, et al.
Published in: BMJ Open. 2019; 9:e032592
2019
Today, 18th of November, is European Antibiotic Awareness Day (EADD), that marks the start of the World Antibiotic Awareness Week (WAAW). WAAW aims to increase global awareness of antibiotic resistance, as well as encourage best practices among the general public, health workers and policy makers to stop the spread of antibiotic resistance. The latest data from the European Centre for Disease Prevention and Control highlights that across the European Union,
2019
We are delighted to see an article on childrenâs antibiotics, co-authored by GARDP R&D Director, Dr Seamus OâBrien, Pentaâs Chief Scientific Officer, Prof. Theo Zakoutlis and Prof. Mike Sharland, from St. Georgeâs, University of London, published in AMR Control, as governments have been discussing AMR at the World Health Assembly.
In R&D for childrenâs antibiotics: a wake-up call the authors explain how AMR has a disproportionate effect on children,
2019
On Tuesday 24th September, the Infection Prevention Disease Society event IP2019 in Liverpool will host the one-day conference: Infection Prevention in Paediatrics: âHand in Handâ- working together for children.
This important event will address paediatric care across areas such as Infection Prevention & Control, Tissue Viability & Wound Care, IV and Infectious Diseases. The programme has been tailored towards all paediatric healthcare workers including: IV Specialist Nurses,
2019
We are pleased to celebrate the milestone achievement of the randomisation of 200 participants in the NeoVanc project. Congratulations to all the NeoVanc team!
A special mention needs to be made on the great effort of investigators, co-investigators and all researchers at recruiting sites involved in this key study on the use of Vancomycin in paediatrics. We look forward to continuing our work together towards reaching the project target of 300 evaluable participants and we wish the NeoVanc team the best of luck!
2017